Management of Psychosis in Parkinson's Disease

Introduction to Quetiapine

The American Geriatrics Society recommends quetiapine as an atypical antipsychotic of choice for treating psychosis in patients with Parkinson's disease, starting with low doses of 25 mg/day and adjusting according to clinical response, with a lower incidence of extrapyramidal symptoms compared to other atypical antipsychotics 1
Quetiapine has a lower risk of worsening motor symptoms compared to other antipsychotics, and it does not require hematologic monitoring, unlike clozapine, with a sedative effect that can be beneficial for sleep disorders 1

The recommended initial dose of quetiapine is 25 mg/day, with gradual adjustment according to response and tolerance, and a maximum habitual dose of 150 mg/day, rarely needed, with a lower starting dose of 12.5 mg/day in elderly patients or those with hepatic insufficiency 1
Quetiapine should be administered preferably at night due to its sedative effects, with monitoring of orthostatic hypotension, especially at the start of treatment, as suggested by the Journal of the American Geriatrics Society 1
Typical dosing range for quetiapine is 150-800 mg/day, with initial dosing often starting at 25-50 mg twice daily, and maintenance dosing varying based on indication 2
A dose of 75 mg may be appropriate for elderly patients, patients with hepatic impairment, or during the initial titration phase 2

Elderly patients require lower doses (12.5-25 mg/day) due to increased sensitivity to sedative effects, with a higher risk of falls due to orthostatic hypotension, according to the Journal of the American Geriatrics Society 3
The American Geriatrics Society recommends caution when using quetiapine with other sedative medications and avoiding concomitant use with high-dose benzodiazepines 1
Elderly patients may require more significant dose reductions due to increased sensitivity to sedative effects, according to the American Geriatrics Society, with a high strength of evidence 1

If quetiapine is not effective or not tolerated, consider clozapine, which is more effective but requires hematologic monitoring due to the risk of agranulocytosis, or pimavanserin, recognized as an alternative in recent guidelines, according to the Journal of the American Geriatrics Society 3

Confirm the diagnosis of psychosis associated with Parkinson's disease, rule out reversible causes, optimize antiparkinsonian treatment, and initiate quetiapine at a low dose (25 mg/night), adjusting the dose every 1-2 weeks according to response and tolerance, with evaluation of efficacy at 4 weeks, and consideration of clozapine or pimavanserin if there is no adequate response 3
Baseline assessment should include complete metabolic panel, lipid profile, blood pressure and heart rate, weight and BMI, and consider ECG in patients with cardiovascular risk factors, as part of a comprehensive management plan 4, 2
Follow-up monitoring should include weight, blood glucose and lipids, blood pressure, and EPS assessment, with specific intervals not provided here but generally following standard clinical practice guidelines 4, 2

Quetiapine therapy requires careful monitoring for side effects, including tardive dyskinesia, orthostatic hypotension, sedation/somnolence, and metabolic effects 2
The risk of tardive dyskinesia increases with longer treatment duration and higher cumulative doses, making early detection crucial 2
Orthostatic hypotension can be minimized by starting with lower doses, and particular caution is necessary in patients with cardiovascular disease 2
Symptoms of tardive dyskinesia involve involuntary movements of the face, tongue, and extremities, and can include laryngeal dystonia, respiratory dyskinesia, dysphonia, and dyspnea 5
The incidence of tardive dyskinesia is approximately 5% per year in young patients 5
If tardive dyskinesia appears, consider drug discontinuation or maintaining the lowest effective dose 2
The American Academy of Pediatrics recommends switching to an antipsychotic with a lower risk of extrapyramidal symptoms, such as aripiprazole, if symptoms persist 5
Adding an anticholinergic agent like benztropine may help manage symptoms of tardive dyskinesia 5
Leukopenia/Neutropenia is a rare but serious side effect, and management includes considering baseline and periodic complete blood counts, and discontinuing medication if WBC drops below 3,000/mm³ or ANC below 1,500/mm³, as recommended by the American Academy of Child and Adolescent Psychiatry 4

The American Academy of Sleep Medicine suggests assessing improvement in daytime somnolence within 2-4 weeks of making changes to medication schedules, with a high strength of evidence 6
Adjustments to minimize daytime somnolence include:
Referral to a sleep specialist should be considered if somnolence persists despite interventions, as recommended by the American Academy of Sleep Medicine, with a high strength of evidence 6
Considering sleep hygiene education as an adjunctive non-pharmacological intervention may be beneficial, as suggested by the American Academy of Sleep Medicine, with a low strength of evidence 6

For female patients planning pregnancy, the Translational Neurodegeneration journal suggests conducting a comprehensive evaluation of risks and benefits, and considering discontinuing quetiapine if benefits do not outweigh risks 7
The need for continued treatment with quetiapine should be reassessed periodically, and the dose adjusted as necessary to minimize the risk of adverse effects 2